Rob Koremans, Recordati CEO

Recor­dati ac­quires EU­SA Phar­ma and its 4 rare dis­ease drugs, but an­a­lysts ques­tion strat­e­gy be­hind the deal

An Ital­ian phar­ma com­pa­ny en­gi­neered a near­ly $850 mil­lion buy­out last week look­ing to ex­pand its rare dis­ease port­fo­lio and fur­ther soak up parts of the US mar­ket, but ques­tions re­main over the drugs in­volved and when they could see pa­tient up­take state­side.

Recor­dati shelled out the cash to ac­quire EU­SA Phar­ma and its port­fo­lio of four rare dis­ease drugs, the com­pa­nies an­nounced Fri­day, al­low­ing Recor­dati to po­si­tion it­self — by its own ac­count — for growth in the US. EU­SA’s top can­di­date for ex­pan­sion is os­ten­si­bly the neu­rob­las­toma drug Qarz­i­ba, ap­proved in the EU for high-risk, new­ly-di­ag­nosed in­di­vid­u­als.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters